Mirum Pharmaceuticals, INC 10-K annual reports

Mirum Pharmaceuticals, Inc. reported significant revenue growth in 2025, driven by its approved rare disease medicines, while actively expanding its clinical pipeline and navigating ongoing patent litigation.

Mirum Pharmaceuticals' 2024 10-K filing highlights increased product sales, ongoing clinical trials, and strategic portfolio expansion in rare disease treatments.

Mirum Pharmaceuticals' 10-K filing details its common stock terms, business strategy, product pipeline, and financial agreements, highlighting its focus on rare and orphan diseases.